Michele Senni, Walter J Paulus, Antonello Gavazzi, Alan G Fraser, Javier Díez, Scott D Solomon, Otto A Smiseth, Marco Guazzi, Carolyn S P Lam, Aldo P Maggioni, Carsten Tschöpe, Marco Metra, Scott L Hummel, Frank Edelmann, Giuseppe Ambrosio, Andrew J Stewart Coats, Gerasimos S Filippatos, Mihai Gheorghiade, Stefan D Anker, Daniel Levy, Marc A Pfeffer, Wendy Gattis Stough, Burkert M Pieske
The management of heart failure with reduced ejection fraction (HF-REF) has improved significantly over the last two decades. In contrast, little or no progress has been made in identifying evidence-based, effective treatments for heart failure with preserved ejection fraction (HF-PEF). Despite the high prevalence, mortality, and cost of HF-PEF, large phase III international clinical trials investigating interventions to improve outcomes in HF-PEF have yielded disappointing results. Therefore, treatment of HF-PEF remains largely empiric, and almost no acknowledged standards exist...
October 21, 2014: European Heart Journal